Rosuvastatin 20mg + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Homozygous Familial Hypercholesterolemia (HoFH)
Conditions
Homozygous Familial Hypercholesterolemia (HoFH)
Trial Timeline
Nov 1, 2014 → Jul 1, 2015
NCT ID
NCT02226198About Rosuvastatin 20mg + Placebo
Rosuvastatin 20mg + Placebo is a phase 3 stage product being developed by AstraZeneca for Homozygous Familial Hypercholesterolemia (HoFH). The current trial status is completed. This product is registered under clinical trial identifier NCT02226198. Target conditions include Homozygous Familial Hypercholesterolemia (HoFH).
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02226198 | Phase 3 | Completed |
Competing Products
20 competing products in Homozygous Familial Hypercholesterolemia (HoFH)